关于
  • English
  • About
    • About Sirona
    • Management
    • Board of Directors
    • Strategic Advisory Board
    • Our Partners
  • TFChem
    • About TFChem
    • Management
    • Team
    • TFChem Laboratory Capabilities
  • Programs
    • Proprietary Platform Technology
    • Pipeline
    • Diabetes – SGLT2 Inhibitor
    • Skincare – Dark Spot Correction
    • Skincare – Anti-Aging / Anti-Wrinkle
    • Antiviral
  • News
    • Sirona News
    • Events
  • Investors
    • Financial Information
    • Financial Reports
    • Investor & Media Kit
    • Newsletter
  • Contact
  • Careers

News

June 29th, 2009

Sirona Biochem Corp. Held its Annual General Meeting

June 9th, 2009

Sirona Biochem Appoints A Leading Biotech Scientist To Progress Its Diabetes And Obesity Drug Discovery Program

May 18th, 2009

Sirona Biochem Corp. (TSX-V: SBM) Attends BIO International, Worlds Largest Biotech Convention

May 1st, 2009

Canada’s First Public Biotech Company since 2007 is launched to help combat the “twin epidemics” – Diabetes and Obesity.

April 29th, 2009

Sirona Biochem Corp. Management Team Restructuring: Mark Senner appointed to President, Christopher Hopton to Chief Financial Officer and John Dougherty to Corporate Development

  • « Previous Page
  • 1
  • …
  • 52
  • 53
  • 54
  • 55
  • Next Page »

Archives

  • About
  • TFChem
  • Programs
  • News
  • Investors
  • Contact

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

Investor enquires: 604.641.4466
info@sironabiochem.com

© 2023 Sirona Biochem.

Sirona Biochem Corp
c/o WeWork
595 Burrard St.
Vancouver, B.C., Canada,V7X 1L4

TFCHEM
Voie de l’innovation
Pharma Parc II Chaussée du Vexin
27100 Val de Reuil, France

Investor enquires: 604.641.4466
info@sironabiochem.com

Enter your info below to subscribe to our newsletter:
Loading